BioSpace News Archive

OpenEye Scientific and Mcule – a leading online marketplace for drug discovery – today announced that OpenEye’s Orion™ molecular design platform now can greatly enhance the ability to search and screen molecules through Mcule’s purchasable compound library.

Alcami, a global pharmaceutical contract development and manufacturing organization (CDMO), announced today that its Board of Directors has appointed Patrick Walsh

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, today announced its partnership with Family Reach, a national organization dedicated to eradicating the financial challenges that accompany a cancer diagnosis

Immune Pharmaceuticals Inc. is in early-stage discussions with United General LTD, a UK Institutional Investment firm. Immune Pharmaceuticals Incs trustee and representatives are exploring options to restructure the company with United General LTD.

Terbium Labs, the premier Digital Risk Protection (DRP) company, today announced a strategic investment from Jefferson Health and Thomas Jefferson University.

The provisional patent describes novel methods for the formulation, delivery, and dosing of psychedelics resulting in a potential reduction in the time spent by patients in the dissociative state.

We invite our shareholders and all interested parties to explore biotech small cap investment opportunities through two days of networking, deal-making and discovery.

Sekur is one app that bundles encrypted email, messaging and file transfer into one solution that incorporates unlimited sized attachments, data loss prevention, anti-phishing, a self-destruct timer and privacy features.

Verantos announced today a collaboration with Amgen to launch an advanced real-world evidence (RWE) program focused on high-validity observational studies.

Artugen Therapeutics, Ltd., a Company that mines the microbiome to discover targeted, therapeutic bacteria for difficult-to-treat infectious and inflammatory diseases, announced today that Laurent Chesnel, Ph.D., Vice President of Research & Development at Artugen Therapeutics, will speak at the Inaugural Microbiome Leaders Conference on March 24 at 5:10pm. Part of the Commercialization of the Microbiome